Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Equities researchers at Leerink Swann issued their FY2019 EPS estimates for shares of Intercept Pharmaceuticals in a research note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz forecasts that the biopharmaceutical company will earn ($16.18) per share for the year. Leerink Swann currently has a “Market Perform” rating and a $110.00 target price on the stock.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($4.84) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($3.74) by $1.10. The business earned $13 million during the quarter, compared to analysts’ expectations of $8.96 million. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. Intercept Pharmaceuticals’s revenue for the quarter was up 2966.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($3.62) EPS. WARNING: “Intercept Pharmaceuticals Inc to Post FY2019 Earnings of ($16.18) Per Share, Leerink Swann Forecasts (ICPT)” was first posted by Financial Market News and is the property of of Financial Market News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.financial-market-news.com/2017/04/21/intercept-pharmaceuticals-inc-to-post-fy2019-earnings-of-16-18-per-share-leerink-swann-forecasts-icpt.html.

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Several other equities research analysts have also recently commented on the stock. Oppenheimer Holdings Inc. reissued an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, April 12th. Wedbush reissued an “outperform” rating and set a $224.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, March 17th. Citigroup Inc set a $240.00 price target on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 28th. BMO Capital Markets boosted their price target on shares of Intercept Pharmaceuticals from $198.00 to $221.00 and gave the stock an “outperform” rating in a research report on Friday, February 24th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, February 23rd. Three analysts have rated the stock with a sell rating, five have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $187.65.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 0.84% during mid-day trading on Friday, hitting $108.09. The stock had a trading volume of 332,171 shares. The company’s market cap is $2.68 billion. The company has a 50-day moving average price of $116.49 and a 200 day moving average price of $117.04. Intercept Pharmaceuticals has a 1-year low of $96.63 and a 1-year high of $177.93.

In related news, insider Lisa Bright sold 254 shares of the company’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $119.48, for a total value of $30,347.92. Following the transaction, the insider now owns 21,695 shares in the company, valued at approximately $2,592,118.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CMO David Shapiro sold 346 shares of the company’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $115.00, for a total transaction of $39,790.00. Following the completion of the transaction, the chief marketing officer now owns 46,023 shares in the company, valued at approximately $5,292,645. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,682 shares of company stock worth $190,137. 9.20% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in ICPT. ING Groep NV purchased a new stake in Intercept Pharmaceuticals during the fourth quarter worth approximately $2,120,000. Emerald Advisers Inc. PA increased its stake in Intercept Pharmaceuticals by 43.7% in the third quarter. Emerald Advisers Inc. PA now owns 76,079 shares of the biopharmaceutical company’s stock worth $12,522,000 after buying an additional 23,129 shares during the period. BlackRock Institutional Trust Company N.A. increased its stake in Intercept Pharmaceuticals by 5.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 437,337 shares of the biopharmaceutical company’s stock worth $71,981,000 after buying an additional 21,523 shares during the period. Carmignac Gestion increased its stake in Intercept Pharmaceuticals by 1.1% in the third quarter. Carmignac Gestion now owns 2,015,192 shares of the biopharmaceutical company’s stock worth $331,680,000 after buying an additional 21,600 shares during the period. Finally, Opus Point Partners Management LLC increased its stake in Intercept Pharmaceuticals by 63.5% in the fourth quarter. Opus Point Partners Management LLC now owns 2,135 shares of the biopharmaceutical company’s stock worth $232,000 after buying an additional 829 shares during the period. Institutional investors and hedge funds own 82.28% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.